Editas Net Income vs Free Cash Flow Analysis

EDIT Stock

USD 2.44 0.07 2.95%

Editas Medicine financial indicator trend analysis is much more than just examining Editas Medicine latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Editas Medicine is a good investment. Please check the relationship between Editas Medicine Net Income and its Free Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Net Income vs Free Cash Flow

Net Income vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Editas Medicine Net Income account and Free Cash Flow. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Editas Medicine's Net Income and Free Cash Flow is 0.82. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Editas Medicine, assuming nothing else is changed. The correlation between historical values of Editas Medicine's Net Income and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Editas Medicine are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Net Income i.e., Editas Medicine's Net Income and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Editas Medicine financial statement analysis. It represents the amount of money remaining after all of Editas Medicine operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Editas Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.Enterprise Value is likely to gain to about 921.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	218.7M	245.7M	247.3M	168.4M
Cost Of Revenue	5.1M	6.3M	177.7M	186.5M

Total Operating Expenses Cost Of Revenue

Editas Medicine fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt
Total Assets		0.12	0.7	0.94	0.95	0.81	0.91	-0.81	-0.83	0.86	0.84	0.88	0.81	0.82	0.99	0.95	0.58	0.78	0.88	0.75	0.89	0.99	0.61	0.95	0.66	0.85
Short Long Term Debt Total	0.12		0.05	0.03	-0.12	0.11	0.05	0.19	-0.04	0.06	0.41	-0.01	0.2	0.16	0.13	0.28	0.75	-0.07	-0.01	0.63	0.04	0.16	0.07	-0.1	-0.04	0.53
Other Current Liab	0.7	0.05		0.76	0.62	0.67	0.59	-0.46	-0.82	0.69	0.5	0.64	0.39	0.69	0.66	0.71	0.49	0.57	0.79	0.62	0.63	0.68	0.26	0.64	0.31	0.52
Total Current Liabilities	0.94	0.03	0.76		0.89	0.81	0.94	-0.82	-0.86	0.95	0.8	0.85	0.67	0.76	0.9	0.93	0.52	0.71	0.88	0.71	0.93	0.92	0.64	0.91	0.72	0.82
Total Stockholder Equity	0.95	-0.12	0.62	0.89		0.66	0.88	-0.81	-0.83	0.82	0.69	0.93	0.82	0.83	0.94	0.87	0.31	0.82	0.89	0.51	0.88	0.91	0.5	1.0	0.59	0.68
Other Liab	0.81	0.11	0.67	0.81	0.66		0.74	-0.77	-0.56	0.68	0.78	0.47	0.42	0.41	0.81	0.71	0.73	0.51	0.6	0.83	0.62	0.88	0.78	0.66	0.74	0.73
Property Plant And Equipment Net	0.91	0.05	0.59	0.94	0.88	0.74		-0.84	-0.81	0.94	0.81	0.81	0.72	0.72	0.88	0.9	0.47	0.57	0.84	0.66	0.97	0.89	0.75	0.88	0.74	0.84
Net Debt	-0.81	0.19	-0.46	-0.82	-0.81	-0.77	-0.84		0.57	-0.7	-0.81	-0.6	-0.44	-0.49	-0.82	-0.68	-0.35	-0.54	-0.65	-0.52	-0.74	-0.84	-0.81	-0.8	-0.87	-0.66
Retained Earnings	-0.83	-0.04	-0.82	-0.86	-0.83	-0.56	-0.81	0.57		-0.87	-0.59	-0.88	-0.75	-0.93	-0.77	-0.88	-0.36	-0.64	-0.99	-0.54	-0.89	-0.77	-0.36	-0.85	-0.41	-0.67
Accounts Payable	0.86	0.06	0.69	0.95	0.82	0.68	0.94	-0.7	-0.87		0.7	0.85	0.72	0.76	0.81	0.92	0.46	0.61	0.87	0.64	0.95	0.82	0.57	0.85	0.61	0.78
Cash	0.84	0.41	0.5	0.8	0.69	0.78	0.81	-0.81	-0.59	0.7		0.57	0.53	0.59	0.85	0.81	0.77	0.48	0.63	0.86	0.72	0.89	0.77	0.69	0.78	0.92
Non Current Assets Total	0.88	-0.01	0.64	0.85	0.93	0.47	0.81	-0.6	-0.88	0.85	0.57		0.86	0.91	0.84	0.89	0.26	0.84	0.9	0.45	0.88	0.78	0.27	0.94	0.42	0.66
Non Currrent Assets Other	0.81	0.2	0.39	0.67	0.82	0.42	0.72	-0.44	-0.75	0.72	0.53	0.86		0.83	0.79	0.83	0.36	0.69	0.78	0.49	0.77	0.74	0.29	0.82	0.3	0.68
Other Assets	0.82	0.16	0.69	0.76	0.83	0.41	0.72	-0.49	-0.93	0.76	0.59	0.91	0.83		0.78	0.87	0.35	0.73	0.94	0.51	0.8	0.74	0.22	0.85	0.33	0.67
Cash And Short Term Investments	0.99	0.13	0.66	0.9	0.94	0.81	0.88	-0.82	-0.77	0.81	0.85	0.84	0.79	0.78		0.91	0.6	0.79	0.83	0.75	0.83	0.99	0.6	0.93	0.67	0.82
Common Stock Shares Outstanding	0.95	0.28	0.71	0.93	0.87	0.71	0.9	-0.68	-0.88	0.92	0.81	0.89	0.83	0.87	0.91		0.62	0.69	0.89	0.78	0.92	0.91	0.54	0.89	0.55	0.89
Non Current Liabilities Total	0.58	0.75	0.49	0.52	0.31	0.73	0.47	-0.35	-0.36	0.46	0.77	0.26	0.36	0.35	0.6	0.62		0.27	0.36	0.97	0.38	0.66	0.54	0.32	0.45	0.8
Other Current Assets	0.78	-0.07	0.57	0.71	0.82	0.51	0.57	-0.54	-0.64	0.61	0.48	0.84	0.69	0.73	0.79	0.69	0.27		0.7	0.43	0.57	0.72	0.14	0.81	0.46	0.49
Other Stockholder Equity	0.88	-0.01	0.79	0.88	0.89	0.6	0.84	-0.65	-0.99	0.87	0.63	0.9	0.78	0.94	0.83	0.89	0.36	0.7		0.54	0.89	0.82	0.41	0.9	0.48	0.68
Total Liab	0.75	0.63	0.62	0.71	0.51	0.83	0.66	-0.52	-0.54	0.64	0.86	0.45	0.49	0.51	0.75	0.78	0.97	0.43	0.54		0.58	0.81	0.63	0.52	0.57	0.89
Property Plant And Equipment Gross	0.89	0.04	0.63	0.93	0.88	0.62	0.97	-0.74	-0.89	0.95	0.72	0.88	0.77	0.8	0.83	0.92	0.38	0.57	0.89	0.58		0.84	0.59	0.9	0.58	0.79
Total Current Assets	0.99	0.16	0.68	0.92	0.91	0.88	0.89	-0.84	-0.77	0.82	0.89	0.78	0.74	0.74	0.99	0.91	0.66	0.72	0.82	0.81	0.84		0.69	0.9	0.71	0.86
Property Plant Equipment	0.61	0.07	0.26	0.64	0.5	0.78	0.75	-0.81	-0.36	0.57	0.77	0.27	0.29	0.22	0.6	0.54	0.54	0.14	0.41	0.63	0.59	0.69		0.5	0.86	0.72
Net Tangible Assets	0.95	-0.1	0.64	0.91	1.0	0.66	0.88	-0.8	-0.85	0.85	0.69	0.94	0.82	0.85	0.93	0.89	0.32	0.81	0.9	0.52	0.9	0.9	0.5		0.59	0.7
Current Deferred Revenue	0.66	-0.04	0.31	0.72	0.59	0.74	0.74	-0.87	-0.41	0.61	0.78	0.42	0.3	0.33	0.67	0.55	0.45	0.46	0.48	0.57	0.58	0.71	0.86	0.59		0.68
Long Term Debt	0.85	0.53	0.52	0.82	0.68	0.73	0.84	-0.66	-0.67	0.78	0.92	0.66	0.68	0.67	0.82	0.89	0.8	0.49	0.68	0.89	0.79	0.86	0.72	0.7	0.68

Click cells to compare fundamentals

Editas Medicine Account Relationship Matchups

Editas Medicine fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	508.9M	572.6M	677.5M	514.3M	499.2M	395.9M
Short Long Term Debt Total	29.1M	26.1M	26.4M	43.9M	36.5M	36.1M
Other Current Liab	24.8M	17.2M	9.9M	20.2M	22.4M	23.5M
Total Current Liabilities	60.0M	58.2M	46.9M	60.1M	63.2M	40.9M
Total Stockholder Equity	262.4M	393.6M	553.6M	360.7M	349.1M	239.8M
Other Liab	163.2M	101.5M	60.9M	60.7M	69.8M	71.4M
Property Plant And Equipment Net	39.6M	39.1M	43.3M	59.2M	45.7M	35.0M
Net Debt	(209.1M)	(113.5M)	(177.1M)	(97.6M)	(87.1M)	(91.5M)
Retained Earnings	(549.2M)	(665.2M)	(857.7M)	(1.1B)	(1.2B)	(1.2B)
Accounts Payable	5.8M	6.4M	5.1M	9.5M	8.3M	5.3M
Cash	238.2M	139.7M	203.5M	141.5M	123.7M	146.9M
Non Current Assets Total	45.0M	153.5M	170.2M	157.6M	158.3M	82.0M
Non Currrent Assets Other	107K	4.7M	6.8M	5.3M	4.7M	3.3M
Other Assets	1.7M	4.7M	6.8M	5.3M	6.0M	6.3M
Cash And Short Term Investments	457.1M	511.8M	619.9M	437.4M	323.1M	338.9M
Common Stock Shares Outstanding	50.0M	58.6M	67.6M	68.7M	76.0M	49.3M
Liabilities And Stockholders Equity	508.9M	572.6M	677.5M	514.3M	499.2M	395.9M
Non Current Liabilities Total	186.5M	120.8M	77.0M	93.5M	86.8M	115.2M
Other Current Assets	6.3M	21.9M	14.4M	7.3M	7.5M	6.1M
Other Stockholder Equity	811.5M	1.1B	1.4B	1.4B	1.6B	1.7B
Total Liab	246.4M	179.0M	123.8M	153.6M	150.1M	156.1M
Property Plant And Equipment Gross	39.6M	39.1M	58.8M	80.7M	72.0M	41.4M
Total Current Assets	463.8M	419.1M	507.3M	356.8M	340.8M	314.0M
Accumulated Other Comprehensive Income	107K	(46K)	(493K)	(3.6M)	198K	207.9K
Property Plant Equipment	39.6M	14.0M	17.1M	15.6M	17.9M	23.1M
Net Tangible Assets	262.4M	393.6M	553.6M	360.7M	414.8M	250.7M
Current Deferred Revenue	23.5M	20.9M	11.3M	8.2M	9.5M	14.2M
Net Receivables	418K	6.0M	267K	5.1M	10.2M	10.7M
Short Term Debt	5.8M	13.6M	20.6M	22.2M	24.3M	14.0M
Short Term Investments	219.0M	262.4M	296.3M	202.8M	199.5M	195.2M
Capital Surpluse	811.5M	1.1B	1.4B	1.4B	1.7B	854.8M
Retained Earnings Total Equity	(549.2M)	(665.2M)	(857.7M)	(1.1B)	(970.3M)	(921.8M)
Capital Lease Obligations	29.1M	26.1M	26.4M	43.9M	36.5M	36.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC